The Patent Finder

Extracellular Vesicles for Vaccine Delivery

Codiak Biosciences, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2020/024023, filed Mar 20, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,992,527Extracellular Vesicles for Vaccine Delivery
In force
 · High confidence
Lonza Sales AGIn force
High confidence
US 12,502,427Extracellular Vesicles for Vaccine Delivery
In force
 · High confidence
Lonza Sales AGIn force
High confidence
Application 17/906,849Extracellular Vesicles for Therapy
Pending
Not granted
Lonza Sales AGPendingNot granted
Application 19/365,432Extracellular Vesicles for Vaccine Delivery
Pending
Not granted
Lonza Sales AGPendingNot granted
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Codiak Biosciences, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited